Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook

Stock Track03-27

CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest financial results.

The sharp rise comes after CHINARES PHARMA reported annual results that exceeded market expectations. The company achieved group revenue of RMB 269.574 billion, representing a year-on-year increase of 4.62%, while profit attributable to shareholders reached RMB 4.045 billion, up 20.73% from the previous year. Earnings per share stood at RMB 0.64, and the company declared a final dividend of RMB 0.122 per share, which represents an increase of approximately 1.35 times compared to the previous year.

Analysts at CLSA noted that both revenue and profit for the full year surpassed market expectations. Additionally, China Merchants Securities International highlighted that while management didn't provide specific numerical guidance for the 2026 fiscal year, they conveyed several positive qualitative signals during the results briefing. The company aims to achieve high single-digit revenue growth and maintain a good growth rate in net profit for the 2026 fiscal year. The dividend payout ratio will be maintained at 30%, with potential increases if no major acquisitions occur. The company also expects impairment pressure to decrease significantly in 2025 and plans to continue its strategic mergers and acquisitions in the blood products sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184445476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184445476","market":"us","top_or_hot":-1,"title":"Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook","media":"Stock Track","content":"<p>CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest financial results.</p><p>The sharp rise comes after CHINARES PHARMA reported annual results that exceeded market expectations. The company achieved group revenue of RMB 269.574 billion, representing a year-on-year increase of 4.62%, while profit attributable to shareholders reached RMB 4.045 billion, up 20.73% from the previous year. Earnings per share stood at RMB 0.64, and the company declared a final dividend of RMB 0.122 per share, which represents an increase of approximately 1.35 times compared to the previous year.</p><p>Analysts at CLSA noted that both revenue and profit for the full year surpassed market expectations. Additionally, China Merchants Securities International highlighted that while management didn't provide specific numerical guidance for the 2026 fiscal year, they conveyed several positive qualitative signals during the results briefing. The company aims to achieve high single-digit revenue growth and maintain a good growth rate in net profit for the 2026 fiscal year. The dividend payout ratio will be maintained at 30%, with potential increases if no major acquisitions occur. The company also expects impairment pressure to decrease significantly in 2025 and plans to continue its strategic mergers and acquisitions in the blood products sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 14:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest financial results.</p><p>The sharp rise comes after CHINARES PHARMA reported annual results that exceeded market expectations. The company achieved group revenue of RMB 269.574 billion, representing a year-on-year increase of 4.62%, while profit attributable to shareholders reached RMB 4.045 billion, up 20.73% from the previous year. Earnings per share stood at RMB 0.64, and the company declared a final dividend of RMB 0.122 per share, which represents an increase of approximately 1.35 times compared to the previous year.</p><p>Analysts at CLSA noted that both revenue and profit for the full year surpassed market expectations. Additionally, China Merchants Securities International highlighted that while management didn't provide specific numerical guidance for the 2026 fiscal year, they conveyed several positive qualitative signals during the results briefing. The company aims to achieve high single-digit revenue growth and maintain a good growth rate in net profit for the 2026 fiscal year. The dividend payout ratio will be maintained at 30%, with potential increases if no major acquisitions occur. The company also expects impairment pressure to decrease significantly in 2025 and plans to continue its strategic mergers and acquisitions in the blood products sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1184445476","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184445476","pubTimestamp":1774593459,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"个股追踪|CHINARES PHARMA盘中大涨5.25%，盈利结果强劲，前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest financial results.The sharp rise comes after CHINARES PHARMA reported annual results that exceeded market expectations. The company achieved group revenue of RMB 269.574 billion, representing a year-on-year increase of 4.62%, while profit attributable to shareholders reached RMB 4.045 billion, up 20.73% from the previous year. Earnings per share stood at RMB 0.64, and the company declared a final dividend of RMB 0.122 per share, which represents an increase of approximately 1.35 times compared to the previous year.Analysts at CLSA noted that both revenue and profit for the full year surpassed market expectations. Additionally, China Merchants Securities International highlighted that while management didn't provide specific numerical guidance for the 2026 fiscal year, they conveyed several positive qualitative signals during the results briefing. The company aims to achieve high single-digit revenue growth and maintain a good growth rate in net profit for the 2026 fiscal year. The dividend payout ratio will be maintained at 30%, with potential increases if no major acquisitions occur. The company also expects impairment pressure to decrease significantly in 2025 and plans to continue its strategic mergers and acquisitions in the blood products sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184445476","isCrawlerRequest":true}